Related Experiment Video
Updated: May 10, 2026
11:30
Use of Frozen Tissue in the Comet Assay for the Evaluation of DNA Damage
Published on: March 24, 2020
Hydroxytyrosol is not genotoxic in vitro
David Auñon-Calles1, Elena Giordano, Susanne Bohnenberger
1Seprox Biotech, Madrid, Spain.
Pharmacological Research
|June 18, 2013
Summary
Hydroxytyrosol (HT), an olive phenol, was evaluated for genotoxicity and mutagenicity. Studies confirmed HT is non-genotoxic and non-mutagenic, even at high doses, supporting its safety in supplements and foods.
Area of Science:
- Food Science
- Toxicology
- Nutraceuticals
Background:
- Hydroxytyrosol (HT) is a potent olive-derived polyphenol with recognized human health benefits, including protecting LDL from oxidative damage.
- HT is a key component of olive mill waste water extracts, which have Generally Recognized As Safe (GRAS) status.
- A long-term study established a No Observed Adverse Effect Level (NOAEL) of 500 mg/kg/d for HT.
Purpose of the Study:
- To assess the genotoxic and mutagenic potential of Hydroxytyrosol (HT).
- To evaluate HT safety for increasing market presence in functional foods and supplements.
Main Methods:
- In vitro genotoxicity testing using the chromosomal aberration assay.
- In vitro mutagenicity testing via the Ames test with Salmonella typhimurium and Escherichia coli strains.
- Testing conducted with and without S9-induced metabolic activation.
Main Results:
- Hydroxytyrosol (HT) demonstrated no evidence of genotoxicity in the chromosomal aberration assay.
- HT showed no mutagenic activity in the Ames test across multiple bacterial strains.
- These findings were consistent with and without metabolic activation.
Conclusions:
- Hydroxytyrosol (HT) is non-genotoxic and non-mutagenic.
- The safety profile of HT is supported at concentrations significantly exceeding typical dietary intake levels.
- Results validate the safety of HT for use in food supplements and functional food products.
Related Concept Videos
01:16In vitro Mutagenesis
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
01:25Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
01:16In-vitro Mutagenesis
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
02:44Oxidation of Alkenes: Syn Dihydroxylation with Osmium Tetraoxide
Alkenes are converted to 1,2-diols or glycols through a process called dihydroxylation. It involves the addition of two hydroxyl groups across the double bond with two different stereochemical approaches, namely anti and syn. Dihydroxylation using osmium tetroxide progresses with syn stereochemistry.
01:20Radical Autoxidation
The oxidation of an organic compound in the presence of air or oxygen is called autoxidation. For example, cumene reacts with oxygen to form hydroperoxide. Autoxidation involves initiation, propagation, and termination steps. Many organic compounds are susceptible to autoxidation—especially ethers in the presence of oxygen, which form hydroperoxides. Even though this reaction is slow, old ether bottles contain small amounts of peroxide, which leads to laboratory explosions during ether...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...